High Notch1 expression affects chemosensitivity of head and neck squamous cell carcinoma to paclitaxel and cisplatin treatment - 18/09/19
, Guojun Li d, Xuezhong Li a, ⁎ Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 7 |
| Iconographies | 4 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | High expression of Notch1 is associated with paclitaxel resistance in HNSCC. |
• | High Notch1 expression is less likely to respond to neoadjuvant chemotherapy and has a worse survival. |
• | In patients without Notch1 expression, those received TPF have better survival than those with PF. |
• | Notch1 expression status predicts therapeutic response to paclitaxel and cisplatin. |
Abstract |
Background |
Notch1 expression has been reported to be associated with chemotherapy resistance and poor prognosis, but the role of Notch1 in head and neck squamous cell carcinoma (HNSCC) sensitivity to anticancer drugs remains unclear. The aim of this study was to evaluate HNSCC sensitivity to paclitaxel and cisplatin in vitro and the chemotherapeutic response of HNSCC to these two drugs in vivo.
Methods |
We used immunohistochemistry to assess Notch1 expression in fresh HNSCC samples treated by PF (cisplatin+5- fluorouracil) and TPF (paclitaxel + cisplatin+5- fluorouracil). We also assessed the sensitivity of two HNSCC cell lines to the Notch1 inhibitor of N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT). The overall and progression-free survival were assessed.
Results |
High Notch1 expression was significantly associated with paclitaxel resistance (P < 0.01). DAPT increased sensitivity to paclitaxel and cisplatin in vitro (P < 0.05). Compared with patients with Notch1 expression, patients without Notch1 expression were more likely to have a response to neoadjuvant chemotherapy with PF (P < 0.01) or TPF (P < 0.01) and had significantly better overall survival (P < 0.05) and progression-free survival (P < 0.05). Among patients without Notch1 expression (but not among patients with Notch1 expression), those who received TPF had significantly better survival than those who received PF (P < 0.05).
Conclusion |
Taken together, our findings may provide some evidence to partially support the predictive value of Notch1 expression in the therapeutic response to paclitaxel and cisplatin.
Le texte complet de cet article est disponible en PDF.Abbreviations : HNSCC, CD-DST, IHC, DAPT
Keywords : Head and neck cancers, Squamous cell carcinomas, Paclitaxel, Cisplatin, Chemosensitivity, Notch1 expression
Plan
Vol 118
Article 109306- octobre 2019 Retour au numéro
Article précédent
- RBCK1 contributes to chemoresistance and stemness in colorectal cancer (CRC)
- Min-Li Liu, Feng Zang, Sheng-Jun Zhang
- Anti-inflammatory effect and potential mechanism of betulinic acid on λ-carrageenan-induced paw edema in mice
- Zhaoping Ou, Jing Zhao, Lijuan Zhu, Lin Huang, Yurong Ma, Chaoyang Ma, Chenxi Luo, Zihan Zhu, Zhihang Yuan, Jing Wu, Rongfang Li, Jine Yi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?